REMAP-CAP is an existing multi-site international adaptive platform trial that was predesigned to adapt in the event of a pandemic. REMAP-CAP for COVID-19 in Australia is supported by APPRISE.
- Current Protocol Documents – Randomized, Embedded, Multifactorial Adaptive Platform trial for Community Acquired Pneumonia (REMAP-CAP)
ASCOT is a clinical trial to generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19. ASCOT was supported by APPRISE.
This activity is coordinated through the Australian Government Department of Health, and is known as the ‘First few X’ (FFX) project‘, where ‘X’ represents the first identified cases of COVID-19.
The Australian FFX project is based on a World Health Organization protocol and is one of many similar studies being conducted worldwide. The Australian FFX project is supported by APPRISE.